Form 4: Prime Medicine Executive Granted Stock Options

Ann L. Lee, Chief Technical Officer of Prime Medicine, Inc., was granted stock options to purchase 275,000 shares of common stock.

Summary

• Ann L. Lee, the Chief Technical Officer of Prime Medicine, Inc. (PRME), was granted stock options on February 27, 2025.
• The stock options allow Lee to purchase 275,000 shares of Prime Medicine's common stock at an exercise price of $2.42 per share.
• The options vest in equal monthly installments over four years, starting on February 27, 2025, contingent upon Lee's continued service with the company.
• The options expire on February 27, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine event, but it signals confidence in the executive and the company's future.

Positives

• The granting of stock options to a key executive like the Chief Technical Officer can be seen as a way to incentivize and retain talent.
• The vesting schedule aligns the executive's interests with the long-term performance of the company.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders. The size and terms of the grant are typical for an executive at this level.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Prime Medicine.
• Comparable companies such as CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize stock options extensively.
• The vesting schedule of 1/48th monthly is a common practice to ensure long-term commitment from the executive.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Chief Technical Officer to drive company performance.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates